Related Experiment Video
Updated: Feb 18, 2026
09:36
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
Published on: June 28, 2019
10.7K
Dopamine: Agonists and Neurodegenerative Disorders
Saba Khanam1, Yasir Hasan Siddique1
1Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, Uttar Pradesh 202002, India.
Current Drug Targets
|November 19, 2017
Summary
This review explores dopamine agonists for Parkinson's disease (PD) treatment. It covers their metabolism, types, and side effects, aiming to reduce adverse outcomes in PD management.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) involves the loss of dopaminergic neurons in the substantia nigra pars compacta.
- Current treatments like Levodopa have limitations, including motor impairments and dyskinesias with long-term use.
- Dopamine agonists are preferred for PD treatment due to their neuroprotective properties, though they also present side effects.
Purpose of the Study:
- To review existing research on dopamine agonists for Parkinson's disease.
- To explore future strategies for mitigating the side effects associated with dopamine agonist therapy.
Main Methods:
- Literature review of studies on dopamine agonists.
- Analysis of dopamine metabolism and agonist properties.
- Evaluation of reported side effects and potential management strategies.
Main Results:
- Detailed overview of dopamine metabolism pathways.
- Classification and characterization of various dopamine agonists.
- Identification of common and potential side effects linked to dopamine agonist use.
Conclusions:
- Dopamine agonists are a key therapeutic option for Parkinson's disease.
- Understanding dopamine metabolism is crucial for developing effective treatments.
- Further research is needed to minimize side effects and optimize therapy for PD patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
01:15Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
01:29Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
01:22Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
01:26Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.4K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K